Antipneumococcal Activities of GAR-936 (a New Glycylcycline) Compared to Those of Nine Other Agents against Penicillin-Susceptible and -Resistant Pneumococci

Abstract

GAR-936, a new glycylcycline, had lower MICs (≤0.016 to 0.125 μg/ml) for 201 penicillin- and tetracycline-susceptible and -resistant pneumococcal strains than tetracycline (≤0.06 to 128 μg/ml), minocycline (≤0.06 to 16.0 μg/ml), or doxycycline (≤0.06 to 32.0 μg/ml). GAR-936 was also bactericidal against 11 of 12 strains tested at the MIC after 24 h, with significant kill rates at earlier time points.